<DOC>
	<DOCNO>NCT00014495</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combine chemotherapy monoclonal antibody therapy treat patient advanced myeloid cancer .</brief_summary>
	<brief_title>Chemotherapy Monoclonal Antibody Therapy Treating Patients With Advanced Myeloid Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose bismuth Bi 213 monoclonal antibody M195 follow cytarabine patient advance myeloid malignancy . - Determine antileukemic effect treatment patient population . - Determine toxicity treatment patient population . - Determine complete remission rate patient treat treatment regimen . OUTLINE : This dose escalation study bismuth Bi 213 monoclonal antibody M195 ( Bi213 MOAB M195 ) . Patients receive cytarabine IV continuously day 1-5 . Beginning day 7 14 , patient receive Bi213 MOAB M195 IV 5 minute 4 time daily 1-4 day . Patient also receive filgrastim ( G-CSF ) subcutaneously daily begin 24 hour final Bi213 MOAB M195 infusion continue blood count recover . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3 6 patient receive escalate dos Bi213 MOAB M195 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Once MTD determine , subsequent patient treat MTD . Patients follow twice weekly 4 week monthly 3 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Pathologically confirm acute myeloid leukemia ( AML ) meet one follow criterion : Newly diagnose AML , age 60 , eligible high priority protocols Newly diagnose AML unable receive anthracyclinecontaining highdose cytarabinecontaining regimen AML relapse AML refractory two course standard induction chemotherapy one course highdose cytarabinecontaining induction chemotherapy Chronic myelogenous leukemia accelerate phase myeloid blast crisis Refractory anemia excess blast ( RAEB ) , RAEB transformation , chronic myelomonocytic leukemia More 25 % bone marrow blast must CD33 positive Not candidate immediate bone marrow transplantation HLAcompatible donor No active CNS leukemia PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 mg/dL ( unless due leukemia Gilbert 's disease ) Alkaline phosphatase great 2.5 time upper limit normal ( ULN ) AST great 2.5 time ULN Renal : Creatinine le 2 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV cardiac disease Pulmonary : No pulmonary disease Other : No detectable antibody monoclonal antibody M195 No serious active uncontrolled infection No concurrent active malignancy require therapy No serious lifethreatening condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy recover Chemotherapy : See Disease Characteristics Prior hydroxyurea allow discontinue study treatment At least 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>